Accéder au contenu
MilliporeSigma

11004638001

Roche

Chymostatin

Synonyme(s) :

Chymostatin, N-(Nα-Carbonyl-Cpd-X-Phe-al)-Phe (Cpd = capreomycidine) (capreomycidine = [S,S]-α-(2-Iminohexahydro-4-pyrimidyl)glycine)

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Numéro CAS:
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
NACRES:
NA.54
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


form

powder

mol wt

Mr = 607.71

packaging

pkg of 10 mg

manufacturer/tradename

Roche

mp

205 °C

solubility

acetic acid: soluble 20 mg/mL

storage temp.

2-8°C

SMILES string

OC(C(NC(NC(C1NC(NCC1)=N)C([F,Cl,Br,I]C)=O)=O)CC2=CC=CC=C2)=O

InChI key

MRXDGVXSWIXTQL-HYHFHBMOSA-N

General description

Chymostatin is a mixture of three components, A, B, and C. The component A being N-[((S)-1-carboxy-2-phenylethyl)-carbamoyl]-α-[2-iminohexahydro-4(S)-pyrimidyl]-L-glycyl-L-leucyl-phenylalaninal. The other two components B and C differ in that the L-leucyl residue is substituted by L-valine and L-isoleucine, respectively.

Application

Chymostatin is a specific inhibitor of α-, β-, γ-, and δ-chymotrypsin.

Biochem/physiol Actions

Chymostatin is a strong inhibitor of many proteases, including chymotrypsin, papain, chymotrypsin-like serine proteinases, chymases, and lysosomal cysteine proteinases such as cathepsins A,B,C, B, H, and L. It weakly inhibits human leucocyte elastase. It is effective at a final concentration of 100 to 200 μg/ml (10 to 100 μM). Chymostatin is often included in protease inhibitor cocktails used with plant extracts.

Preparation Note

Working concentration: 6 to 60 μg/ml (10 to 100 μM)
1 U chymotrypsin is inhibited to 49% of the original activity by 1.8 μg of chymostatin.
Thin-layer chromatography: butanol/methanol/H2O = 4 / 1 / 2
Working solution: Soluble in glacial acetic acid or DMSO to 20 mg/ml. Sparingly soluble in water, methanol, or ethanol. Insoluble in ethyl acetate, petroleum and ethyl ethers, hexane, or chloroform (CHCl3).
It is recommended to dissolve the inhibitor in 1% acetic acid in higher concentration and to adjust the concentration wanted with phosphate buffer, 0.05 M, pH 7.0, which is common for chymotrypsin assay.
CAUTION: DMSO (Dimethyl sulfoxide) will permeate the skin, carrying solubilized protease inhibitors. Always wear appropriate protection for eyes, skin, etc.
Storage conditions (working solution): -15 to -25 °C
Dilute solutions should be stored frozen in aliquots at -15 to -25 °C and are stable for approximately one month. Avoid repeated freezing. Growth of microorganisms should be avoided as proteases from microbial origin may hydrolyze the peptides.
C31H41N7O6
Solubility testing in glacial acetic acid at 10 mg/ml yields a clear solution, which is usually colorless, but can be yellow in appearance. It is reportedly also soluble in DMSO; only slightly soluble in water and short-chain alcohols; insoluble in ethyl acetate, butyl acetate, ether, hexane, and petroleum ether. Stock solutions (10 mM) can be prepared in DMSO and are stable for months at -20 °C. Stock solutions can also be made in 0.1 M HCl. Dilute solutions (10-100 μM) are only stable for several hours, due to oxidation of the terminal aldehyde.

Analysis Note

Performance tested.

Other Notes

For life science research only. Not for use in diagnostic procedures.


Still not finding the right product?

Explore all of our products under


Classe de stockage

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



The structure of chymostatin, a chymotrypsin inhibitor.
K Tatsuta et al.
The Journal of antibiotics, 26(11), 625-646 (1973-11-01)
Verena van der Heide et al.
Cell reports, 38(11), 110508-110508 (2022-03-06)
Concerns that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), may cause new-onset diabetes persist in an evolving research landscape, and precise risk assessment is hampered by, at times, conflicting evidence.



Numéro d'article de commerce international

RéférenceGTIN
1100463800104061838693761